Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Janux Therapeutics
Biotech
Astellas says 'I do' to Vir's T-cell engager in $1.7B deal
Vir is trading a stake in its PSMA-targeted bispecific VIR-5500 for a $335 million upfront and near-term capital infusion from Astellas.
Angus Liu
Feb 23, 2026 5:00pm
Cardiff Oncology churns C-suite—Chutes & Ladders
Jan 30, 2026 8:30am
BMS pens $850M tumor pact with T-cell engager biotech Janux
Jan 22, 2026 8:35am
Analyst deems Janux's stock spiral an 'overreaction'
Dec 2, 2025 11:14am
Takeda taps Julie Kim as new CEO—Chutes & Ladders
Jan 31, 2025 8:30am
Janux's T-cell engager makes waves, again, with new data drop
Dec 3, 2024 11:40am
